When it comes to the use of PD-1 inhibitors in stomach cancer, the FDA has put its money where its mouth is. | After ...

Bristol Myers BMY announced that the European Commission (EC) has approved the subcutaneous formulation of Opdivo (nivolumab) ...

Bristol-Myers Squibb and BioNTech announced a major deal worth up to $11 billion in early June. Click here to find out why I ...

Opdivo vs. Keytruda This month there was disappointment for Bristol-Myers Squibb which has run into yet another hurdle trying to extend the use of its immuno-oncology blockbuster Opdivo into new ...

Leerink Partners previews the drugs likely to be subject to the Inflation Reduction Act’s next price negotiations as the ...

The Scottish Medicines Consortium has ruled that Bristol-Myers Squibb's Opdivo (nivolumab) is cost-effective in locally advanced or metastatic squamous non-small cell lung cancer, whose disease ...

US pharma major Bristol Myers Squibb has announced that the European Commission (EC) has approved a new Opdivo (nivolumab) ...

Despite its success in advanced melanoma, Bristol Myers Squibb’s fixed-dose PD-1/LAG-3 combo, Opdualag, failed to move the ...

Bristol Myers on Wednesday said the European Commission approved the subcutaneous formulation of Opdivo for use across multiple adult solid tumors as monotherapy, monotherapy maintenance following ...

New formulation supports adaptable care delivery in oncology settings with limited capacity or remote patient populations ...

The European Commission (EC) has granted approval to Bristol Myers Squibb's (BMS) perioperative regimen of neoadjuvant Opdivo (nivolumab), combined with chemotherapy and followed by adjuvant ...